Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by touktoukon Nov 13, 2009 7:01pm
685 Views
Post# 16486049

Net profit for the quarter......

Net profit for the quarter......

ProMetic Reports Its Third Quarter 2009 Highlights and Financial Results

MONTREAL, QUEBEC--(Marketwire - Nov. 13, 2009) - ProMetic Life Sciences Inc. (TSX:PLI)

- Net Profit of
.2 M in Q3 2009 vs. Net Losses of $3.6 M in Q3 2008


- YTD Sales of $9.3 M vs. $6.2 M in 2008, up 50%

- YTD Net Losses reduced to $7.0 M vs. $15.0 M in 2008, down 53%

- Significant YTD reduction of cash used in operations - $2.5 M vs. $14.1 M, down 82%


I

Bullboard Posts